Med Business World

Your source for healthcare business

Kari Hagen

New clinical trial shows that algae-based omega-3 lecithin AlmegaPL® provides better cardiovascular health support compared to traditional omega-3 fish oils

Qualitas Health, LLC (dba iwi life) The results of a new clinical trial show evidence that the microalgae-derived AlmegaPL®, the foundational ingredient produced by iwi life™, delivers clinically relevant results decreasing triglycerides by 14% and remnant cholesterol such as very-low-density lipoprotein (VLDL)…

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12…

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247. Dr. Ashraf Ibrahim, PhD, FAAM, FECCM, Professor…

CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors

CDR-Life Inc. today announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for CDR404, its lead program in development as a precision immunotherapy for solid tumors. First of its kind, CDR404 is…

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced positive topline results from its REPOSE clinical study comparing standard-of-care neurectomy of symptomatic neuroma to neurectomy and protection of the…

Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the findings of the Phase 1b portion of the Phase 1b/2 study for the second-line treatment of patients with KRAS-mutated…

Equality Health Brings Proven “Medicaid-First” Value-Based Care Model to Virginia

Equality Health, a national leader in value-based care, today announced its latest expansion into the Commonwealth of Virginia, offering its proven value-based care (VBC) model to primary care providers (PCPs) and health plans throughout the state. Proudly “Medicaid-first,” Equality Health aims…

Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery

Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and Evive Biotech, a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwide, today announced a collaboration agreement on antibody…

Harvard Radcliffe Institute’s Schlesinger Library to Receive Dr. Susan M. Love’s Intellectual Properties Collection

The Arthur and Elizabeth Schlesinger Library on the History of Women in America in Cambridge, Massachusetts, holds the largest collection of papers by important women in the United States. The Library will receive the life’s work of papers and articles by renowned…

Hovione acquires ExtremoChem and its portfolio of proprietary sugars to support customers with stabilization and delivery of biopharmaceuticals

Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, today announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on the synthesis, development, and commercialization of bio-inspired synthetic sugars, targeting enhanced stabilization,…